Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review

Hamblin, Ross; Karavitaki, Niki

doi:10.1016/j.arcmed.2023.102910

Cited by 7 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Bancos et al had comparable results, with 24.8% in patients versus 17.1% in the control group, but was non-significant [ 20 ]. Overall, there is a large variation in the prevalence of ICDs in different studies (ranging from 0% to 60%) [ 21 ]. This large difference may suggest social and economic factors affecting the occurrence and even the type of ICDs [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Impulse Control Disorders in Southern Iraqi Patients Medicated With Cabergoline for Prolactinoma

Mohammad,

Alidrisi,

Mansour

2024

Cureus

View full text Add to dashboard Cite

Background: Among the patient population in Basrah, Iraq, prolactinoma is the most commonly found pituitary tumor. Impulse control disorders (ICDs) were reportedly associated with these patients being treated with cabergoline. This study aimed to assess the prevalence of ICDs in cabergoline-treated prolactinoma patients versus healthy, matched controls. Methods: This cross-sectional case-control study was conducted at the Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC) in Basrah, southern Iraq, from January 2023 to May 2023. It included 30 cabergoline-treated prolactinoma patients and 30 healthy, matched controls. The questionnaire for ICDs in Parkinson's disease was used as a screening tool. Following this, positively screened patients were evaluated using validated criteria accordingly to diagnose impulse control disorders.Results: The ICDs were diagnosed in nine (30%) cabergoline-treated prolactinoma patients versus two (6.7%) in control (p = 0.02). The most frequent ICD types were hypersexuality and binge eating, while no patient reported pathological gambling. Three patients reported multiple types of ICDs. The patients' sociodemographic characteristics, prolactinoma duration and size, and cabergoline dose did not correlate significantly with ICD diagnosis.Conclusions: Treatment with cabergoline is associated with the development of ICDs. Therefore, clinicians should be aware of this disabling side effect to ensure its early detection and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%